UCP2 and glaucoma: These data demonstrate that Ucp2 decreases RGC loss due to elevated IOP over a sub-acute timeframe, and also that the beneficial effects of Ucp2 are cell autonomous, as Ucp2-overexpression in GFAP-positive glia is insufficient to decrease glaucoma-related RGC loss (Figure 5C).